Men's Blog from Canada
In: Medicine
12 Dec 2014Omalizumab (administered subcutaneously every 2 or 4 weeks per serum IgE levels and body weight) has been assessed in randomized controlled trials in patients with moderate-to-severe asthma who remain symptomatic despite receiving ICS therapy. The ICS dose remained constant during the first 16 weeks and was tapered over the next 8 to 12 weeks. Adding […]
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Quisque sed felis. Aliquam sit amet felis. Mauris semper, velit semper laoreet dictum, quam diam dictum urna, nec placerat elit nisl in quam. Etiam augue pede, molestie eget, rhoncus at, convallis ut, eros. Aliquam pharetra.